Compare LCNB & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCNB | IPSC |
|---|---|---|
| Founded | 1877 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.1M | 248.1M |
| IPO Year | 1999 | 2021 |
| Metric | LCNB | IPSC |
|---|---|---|
| Price | $19.93 | $1.78 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $20.83 | $4.75 |
| AVG Volume (30 Days) | 20.2K | ★ 972.2K |
| Earning Date | 10-15-2026 | 11-20-2026 |
| Dividend Yield | ★ 4.49% | N/A |
| EPS Growth | 68.04 | ★ 91.30 |
| EPS | ★ 1.35 | N/A |
| Revenue | $6,445,000.00 | ★ $109,164,000.00 |
| Revenue This Year | $11.08 | N/A |
| Revenue Next Year | $0.51 | N/A |
| P/E Ratio | $14.36 | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $14.83 | $0.44 |
| 52 Week High | $21.32 | $2.97 |
| Indicator | LCNB | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 53.86 | 60.52 |
| Support Level | $18.44 | $1.29 |
| Resistance Level | $20.48 | $2.45 |
| Average True Range (ATR) | 0.55 | 0.16 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 56.25 | 80.19 |
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.